当前位置: X-MOL 学术Asia Pac. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
Asia-Pacific Journal of Clinical Oncology ( IF 1.4 ) Pub Date : 2022-07-13 , DOI: 10.1111/ajco.13807
Imogen Walpole 1 , Belinda Lee 1, 2, 3 , Jeremy Shapiro 4, 5 , Benjamin Thomson 6, 7 , Lara Lipton 4, 7, 8 , Sumitra Ananda 7, 8 , Val Usatoff 4, 8 , Sue-Ann Mclachlan 3, 9 , Brett Knowles 7, 9 , Adrian Fox 9, 10 , Rachel Wong 2, 5, 10, 11 , Prasad Cooray 12 , Matthew Burge 13 , Kate Clarke 14 , Sharon Pattison 15 , Mehrdad Nikfarjam 3, 16, 17 , Niall Tebbutt 16 , Marion Harris 18 , Adnan Nagrial 19 , Rob Zielinski 20, 21, 22 , Cheng Ean Chee 23 , Peter Gibbs 2, 3
Affiliation  

Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable

中文翻译:


新辅助化疗在澳大利亚人群交界性可切除胰腺导管腺癌中的应用和结果



当胰腺导管腺癌 (PDAC) 处于可切除边缘时,建议使用新辅助 (NA) 化疗
更新日期:2022-07-13
down
wechat
bug